Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of tiragolumab + atezolizumab intravenous fixed-dose combination in PD-L1-positive advanced solid tumors
CTR20241480Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tiragolumab, atezolizumab in Nonhematologic neoplasms, sponsored by Roche. Started Feb 2025; status: completed.
02
Drugs
tiragolumabatezolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20241480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241480.